Haleos Labs Limited vs Novartis India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Haleos Labs Limited is ₹ 1511 as of 04 May 10:16 . The P/E Ratio of Haleos Labs Limited changed from 11 on March 2021 to 16.2 on March 2025 . This represents a CAGR of 8.05% over 5 yearsThe P/E Ratio of Novartis India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Haleos Labs Limited changed from ₹ 149.61 crore on March 2021 to ₹ 326.64 crore on March 2025 . This represents a CAGR of 16.90% over 5 yearsThe Market Cap of Novartis India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Haleos Labs Limited for the Dec '25 is ₹ 94.97 crore as compare to the Sep '25 revenue of ₹ 81.79 crore. This represent the growth of 16.11% The revenue of Novartis India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Haleos Labs Limited for the Dec '25 is ₹ 14.23 crore as compare to the Sep '25 ebitda of ₹ 13.99 crore. This represent the growth of 1.72% The ebitda of Novartis India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Haleos Labs Limited changed from ₹ 7.1 crore to ₹ 6.65 crore over 7 quarters. This represents a CAGR of -3.67% The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Haleos Labs Limited changed from 3.44 % on March 2021 to 2.12 % on March 2025 . This represents a CAGR of -9.23% over 5 yearsThe Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 years .

About Haleos Labs Limited

SMS Lifesciences India Limited was incorporated originally as 'Potluri Real Estate Private Limited' on May 31, 2006.
The Company's name was changed to 'Potluri Packaging Industries Private Limited' on 6 November, 2013 and again changed to 'SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector.
The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016. The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates.
The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments.

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

FAQs for the comparison of Haleos Labs Limited and Novartis India Ltd

Which company has a larger market capitalization, Haleos Labs Limited or Novartis India Ltd?

Market cap of Haleos Labs Limited is 445 Cr while Market cap of Novartis India Ltd is 2,550 Cr

What are the key factors driving the stock performance of Haleos Labs Limited and Novartis India Ltd?

The stock performance of Haleos Labs Limited and Novartis India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Haleos Labs Limited and Novartis India Ltd?

As of May 4, 2026, the Haleos Labs Limited stock price is INR ₹1474.9. On the other hand, Novartis India Ltd stock price is INR ₹1032.9.

How do dividend payouts of Haleos Labs Limited and Novartis India Ltd compare?

To compare the dividend payouts of Haleos Labs Limited and Novartis India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.